Faculty
Tae Hyo Kim
MD, PhD
Currents Position
Professor
Chairman of department of Urology, Dong-A University Medical Center
Director of Dong-A University Robotic Surgery Center
Education
| 1992 – 2000 M.D. | Dong-A University, College of Medicine, Busan, Korea |
| 2002 – 2004 M.S. | Dong-A University Graduate School, Busan, Korea |
| 2008 – 2010 Ph. D | Dong-A University Graduate School, Busan, Korea |
Postgraduate & Faculty Appointments
| 2001-2002 | Internship, Dong-A University. Medical Center, Busan, Korea |
| 2002-2006 | Residency course in Department of Urology, Dong-A University Medical Center, Busan, South Korea |
| 2006-2008 | Fellowship in Department of Urology, Dong-A University Medical center, Busan, South Korea |
| 2009-2010 | Instructor fellow in Department of Urology, Dong-A University Medical Center, Busan, South Korea |
|
2010-2015
2017-2018
2016-2019 |
Assistant professor in Department of Urology, Dong-A University Medical Center, Busan, South Korea Visiting scholarship training, University of North Carolina Department of Urology, USA Associate professor in Department of Urology, Dong-A University Medical Center, Busan, South Korea |
| 2020 – | Director, department of urology, Dong-A university medical center and Dong-A University Robotic Surgery Center |
2022 – Professor in department of urology, Dong-A University Medical
School, Busan, South Korea
Activities in Academic Society
President, Korean Urological Surgery Research Society
General Secretary, Korean Society of endourologyl and robotics
Vice chairman, Hannam urological Association
Vice chairman, Korean Society for Sexual Medicine and Andrology
Published article
Evaluation of Clinical Outcomes of Prostatic Urethral Lift for Benign Prostatic Hyperplasia: An Asian Population Study. Kim JH, Lee KS, Kim TH. World J Mens Health. 2019 Jul 30
The Safety and Feasibility of the Single-Port Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair Through Retropubic Radical Prostatectomy Scar, Prospective, Case Series. Chung JH, Kim TH, Lee KS, Cho JM, Kim KS, Choi HY, Lee SW. J Laparoendosc Adv Surg Tech A. 2018 Dec;28(12):1458-1462
Efficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial. Chung JH, Oh CY, Kim JH, Ha US, Kim TH, Lee SH, Han JH, Bae JH, Chang IH, Han DH, Yoo TK, Chung JI, Kim SW, Jung J, Kim YI, Lee SW. Curr Med Res Opin. 2018 Oct;34(10):1793-1801
The Safety and Feasibility of the Single-Port Laparoscopic Repair of Intraperitoneal Bladder Rupture. Chung JH, Kim KS, Choi HY, Moon HS, Kim YT, Park SY, Oh CY, Lee KS, Kim TH, Lee SW. J Endourol. 2018 May;32(5):403-409.
Clinical outcomes of the sequential use of pazopanib followed by everolimus for the treatment of metastatic renal cell carcinoma: A multicentre study in Korea. Kim JH, Lee W, Kim TN, Nam JK, Kim TH, Lee KS. Can Urol Assoc J. 2018 Jan;12(1):E15-E20.
Clinicopathologic Characteristics and Treatment Outcomes of Penile Cancer. Nam JK, Lee DH, Park SW, Kam SC, Lee KS, Kim TH, Kim TS, Oh CK, Park HJ, Kim TN. World J Mens Health. 2017 Apr;35(1):28-33
Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms. Park YH, Kim TH, Lee SW, Chung BH, Cho JS, Lee JY. Low Urin Tract Symptoms. 2017 May;9(2):75-81
Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study. Seo WI, Kang PM, Kim TH, Moon KH, Chung JM, Lee DH, Kim IY, Min K, Chung J, Kim W, Kang DI. World J Mens Health. 2014 Dec;32(3):159-66.
Reasons for prescription change of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Kim TN, Nam JK, Lee KS, Kim TH, Park SW, Shin DG, Park HJ, Lee W, Lee ZZ, Chung MK. Urology. 2014 Aug;84(2):427-32.
The Efficacy and Safety of Tadalafil 5 mg Once Daily in the Treatment of Erectile Dysfunction After Robot-Assisted Laparoscopic Radical Prostatectomy: 1-Year Follow-up. Seo YE, Kim SD, Kim TH, Sung GT. Korean J Urol. 2014 Feb;55(2):112-9
Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Lee GT, Kang DI, Ha YS, Jung YS, Chung J, Min K, Kim TH, Moon KH, Chung JM, Lee DH, Kim WJ, Kim IY. Br J Cancer. 2014 Mar 18;110(6):1634-44.
Interfraction prostate movement in bone alignment after rectal enema for radiotherapy.
Seo YE, Kim TH, Lee KS, Cho WY, Lee HS, Hur WJ, Choi Y. Korean J Urol. 2014 Jan;55(1):23-8
Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Kang DH, Lee JY, Chung JH, Cho JM, Lee SH, Park J, Kim TH, Yoo TK, Lee SW. Int J Clin Pract. 2012 Aug;66(8):813-820
Effect of Bladder Neck Preservation and Posterior Urethral Reconstruction during Robot-Assisted Laparoscopic Radical Prostatectomy for Urinary Continence. You YC, Kim TH, Sung GT. Korean J Urol. 2012 Jan;53(1):29-33
Radiofrequency ablation of renal tumors: our experience. Kim JH, Kim TH, Kim SD, Lee KS, Sung GT. Korean J Urol. 2011 Aug;52(8):531-7.
Tamsulosin Monotherapy versus Combination Therapy with Antibiotics or Anti-Inflammatory Agents in the Treatment of Chronic Pelvic Pain Syndrome. Kim TH, Lee KS, Kim JH, Jee JY, Seo YE, Choi DW, Sung YG, Kong GS, Kim DW, Cho WY. Int Neurourol J. 2011 Jun;15(2):92-6.
Clinical Trials
|
Indication of Trial |
Clinical Phase of Trial |
Role in Trial |
Year in which trial was conducted |
|
전이성 또는 절제 불가능한 신세포암 (RCC) 이 있는 시험대상자에서 REGN2810 (항-PD-1)과 병용투여 한 Pexa-Vec (티미딘키나아제 비활성화 GM-CSF 우두 바이러스)의 용량 증량, 제 1b상 임상시험 |
I |
Co- Investigator |
2018~Ongoing |
|
양성 전립선 비대증과 발기부전 치료를 위해 탐스로신염산염 0.4mg과 타다라필 5mg의 병용투여를 대체할 환자를 대상으로 구구탐스캡슐을 사용할 시의 안전성•유효성 평가를 위한 사용성적조사 |
IV |
Co- Investigator |
2018~Ongoing |
|
과민성방광 환자를 대상으로 Solifenacin fumarate 12주 요법의 유효성 및 안전성을 조사하기 위한 비중재적, 전향적, 다기관, 관찰연구 |
IV |
Co- Investigator |
2017~Ongoing |
|
만성 부고환염으로 부고환 절제술 시행 후 음낭 통증을 감소시키기 위해서 사용되는 메디클로®의 안전성 및 유효성을 평가하기 위한 다기관, 무작위 배정, 전향적, 단일눈가림, 연구자임상시험 |
IV |
Principal Investigator |
2016~2018 |
|
전립선비대증의 치료를 위한 경요도전립선절제술 후 유착방지를 위해서 사용되는 유착방지제 메디클로®의 안전성 및 유효성을 평가하기 위한 다기관,무작위배정,전향적,단일눈가림,연구자임상시험 |
IV |
Principal Investigator |
2016~2018 |
|
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder |
III |
Co- Investigator |
2014~2017 |
|
A randomized, double-blind, parallel-group, placebo- and active- controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of solifenacin succinate and mirabegron compared to solifenacin succinate and mirabegron monotherapy in the treatment of overactive bladder |
III |
Co- Investigator |
2013~2015 |
|
양성 전립선비대증 환자를 대상으로 HGP0412 와 HIP1402의 유효성과 안전성을 평가하기 위한 다기관, 무작위배정, 이중눈가림, 3상 임상시험 |
III |
Principal Investigator |
2014~2015 |
|
Adjuvant axitinib treatment of renal cancer: A randomized double-blind Phase 3 study of adjuvant axitinib vs. placebo in subjects at high risk of recurrent RCC |
III |
Co- Investigator |
2012~Ongoing |
|
Treatment patterns and patient reported outcomes in Benign Prostatic Hyperplasia patients with Overactive Bladder symptom |
IV |
Principal Investigator |
2012 |
|
전이성 신장세포암 환자에서 BMI-rh-IL2(재조합 인터류킨-2) 단독 투여 시의 약물동태 및 안전성과 유효성을 평가하기 위한 임상시험 |
I/II |
Principal Investigator |
2011~2014 |
|
Risk factors for acute urinary retention according to administration of anticholinergics in OAB with BPH |
IV |
Principal Investigator |
2011~2012 |
|
The safety and effectiveness of Miroderafil (Mvix Ⓡ)50mg Daily administration for erectile dysfunction: Multicenter, Double-blind, placebo control study |
IV |
Principal Investigator |
2010~2011 |
|
178-CL-090: Phase III Study of YM178 – A randomized, double-blind, parallel group, placebo and active controlled, multi-center study in subjects with symptoms of overactive bladder |
III |
Co- Investigator
|
2010~2011 |
|
12-Week,Randomized,Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter (Trial to Evaluate the Efficacy and Safety of Fesoterodine in comparison to Tolterodine ER in patients with Overactive Bladder) (A0221046) |
IIIb/IV |
Co- Investigator |
2010~2011 |
|
The Effect of Tamsulosin 0.2mg in Patients with Chronic Pelvic Pain Syndrome (CPPS) : Multicenter, Randomized, Prospective Study |
IV |
Co- Investigator |
2008~2009 |
|
Benign prostatic hyperplasia |
PMS |
Co- Investigator |
2004 |
